SPARC and osteosarcoma: Osteonectin is known to have tumor-progressing or -suppressing properties, depending on the surrounding cellular environment, and seems to be a negative prognostic marker in human osteosarcoma patients [50], indicating a valuable candidate gene that might influence the progression of osteosarcoma.